

Remarks

As directed by the Notice to Comply, this amendment directs the Office to replace the attached copy of the sequence listing in the specification. The content of such sequence listing in computer readable form does not include matter which goes beyond the disclosure of the U.S. Application as originally filed. Therefore, Applicant asserts that the present submission includes no new matter.

Respectfully submitted,

/Robert L. Sharp/
Robert L. Sharp
Attorney for Applicants
Registration No. 45,609
Phone: 317-651-1541

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

October 7, 2009